Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$18.55MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Najat Khan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 600
- Beta
- 1.03
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.66
Financials
Revenue
$18.55M+2052.2%Net Income
$-119.04MEBITDA
$-102.48MFree Cash Flow
$-77.81MEPS (diluted)
$-0.22Shares Outstanding (diluted)
543.00M+222.6%Operating Expenses
$131.68MCash & Debt
$549.85MRevenue by Segment (annual)
$74.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $74.68M | $-644.76M | $-1.44 |
| 2024 | $58.84M | $-463.66M | $-1.69 |
| 2023 | $43.88M | $-328.07M | $-1.58 |
| 2022 | $39.68M | $-239.48M | $-1.36 |
| 2021 | $10.00M | $-186.48M | $-1.05 |
| 2020 | $3.41M | $-87.01M | $-0.52 |
| 2019 | $1.71M | $-62.52M | $-0.37 |
Valuation
RXRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-66.67%Social Signal Score
Mentions (23)
- Newsfool.com·4d ago·Negative
Why Recursion Pharmaceuticals Stock Is Up Today One of Recursion Pharmaceuticals' internally developed drugs is advancing to late-stage clinical trials. While only aiming at a relatively small opportunity, Wednesday's announcement affirms the value of Recursion's AI-powered pre-clinical-testing solution.
View source ↗ - Newsfinbold.com·11d ago·Positive
2 healthcare stocks to turn $10 into $100 by next year Healthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence (AI) boom.
View source ↗ - Newsglobenewswire.com·11d ago·Negative
Recursion to Participate in Upcoming Investor Conferences Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference London — Wednesday, November 18, 2026 Evercore 9th Annual Healthcare Conference — Monday, November 30, 2026 Citi's 2026 Global Healthcare Conference — Tue…
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Najat Khan - CEO, President & Director Vicki Goodman - Chief Medical Officer Ben Taylor - CFO & President of Recursion UK Conference Call Participants Evelien Dekker Bryson Katona Jesse Laster Lindsay Huff Laura Laster Presentation Najat Khan CEO, President & Director Good morning, everyone, and thank you for join…
View source ↗ - Newsmarketbeat.com·19d ago·Positive
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call Recursion Pharmaceuticals NASDAQ: RXRX reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029.
View source ↗ - Newszacks.com·20d ago·Negative
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.36 per share a year ago.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
Recursion Appoints Fred Hassan as Chair of the Board Salt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, effective October 31, 2026 Mr. Hassan arrives with a strong track record of more than four decades in the pharmaceutical industry. He has grown global businesses and led teams that brought multiple me…
View source ↗ - Newszacks.com·23d ago·Neutral
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.03, moving 4.95% from the previous trading session.
View source ↗ - Newszacks.com·27d ago·Neutral
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.8, signifying a +2.7% move from its prior day's close.
View source ↗ - Newszacks.com·33d ago·Negative
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing Recursion Pharmaceuticals (RXRX) reached $3.66 at the closing of the latest trading day, reflecting a +1.39% change compared to its last close.
View source ↗ - Newsglobenewswire.com·38d ago·Negative
…00 Million Underwritten Offering of Class A Common Stock Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at a price of $3.25 per share. All of the shares are to be sold by Recursion.
View source ↗ - Newszacks.com·41d ago·Neutral
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.01, moving 8.03% from the previous trading session.
View source ↗ - Newszacks.com·47d ago·Neutral
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.
View source ↗ - Newszacks.com·55d ago·Neutral
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
View source ↗ - Newszacks.com·59d ago·Negative
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
View source ↗ - Newsbusinesswire.com·62d ago·Negative
…odel CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion's RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into …
View source ↗ - Newszacks.com·67d ago·Neutral
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·73d ago·Neutral
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
View source ↗ - Newszacks.com·79d ago·Neutral
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·80d ago·Positive
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
View source ↗ - Newsseekingalpha.com·104d ago·Negative
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generat
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.20 per share
Typical surprise -0.5% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$-0.22 vs $-0.22miss
- Wed, Aug 5$-0.25 vs $-0.24miss
- Wed, May 6$-0.22 vs $-0.30beat
- Wed, Feb 25$-0.21 vs $-0.28beat
- Wed, Nov 5$-0.36 vs $-0.38beat
- Tue, Aug 5$-0.41 vs $-0.35miss
Estimates and results for RXRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RXRX officers and directors.
- Bought
- —
- Sold
- $4.3m
0 trades
27 trades
- Borgeson Blakesold
- Borgeson Blakesold
- Hershberg Robertsold
- Khan Najatsold
- Borgeson Blakesold
- Borgeson Blakesold
- Borgeson Blakesold
- Bumpus Namandjesold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RXRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
